| Manufacturer |
Novo Nordisk |
Eli Lilly and Company |
| Pricing |
Manufacturer self-pay options:
- Promotional Offers: Eligible new patients may qualify for introductory pricing starting at approximately $199 per month during certain promotional periods.
- Standard Self-Pay: Manufacturer injection offers may range from approximately $349 to $499 per month, depending on dosage and eligibility.
- Retail Pricing: Prices without manufacturer assistance may exceed $1,000 per month.
|
Manufacturer savings and retail pricing:
- Savings Card: Eligible commercially insured patients with coverage may pay as little as $25 for a prescription covering up to three months, subject to program limits.
- Retail Pricing: Uninsured retail prices may exceed $1,000 for a four-week supply, depending on pharmacy and dosage.
- Eligibility: Actual costs depend on insurance coverage, savings-program requirements, and prescribed dosage.
|
| Insurance Coverage |
- Commercial Insurance: Many plans cover Ozempic for eligible adults with type 2 diabetes.
- Medicare Part D: Coverage may be available for medically eligible beneficiaries.
- Weight Loss Alone: Generally not covered because Ozempic is not specifically approved for weight management.
|
- Commercial Insurance: Many plans cover Trulicity for eligible patients with type 2 diabetes.
- Medicare Part D: Coverage may be available according to plan formularies and eligibility.
- Prior Authorization: Some insurers require documentation of diabetes diagnosis or previous treatments.
|
| Main Purpose |
Improve blood sugar control in adults with type 2 diabetes. |
Improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes. |
| Secondary Purposes |
- Cardiovascular Protection: Reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
- Kidney Protection: Reduce certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.
|
- Cardiovascular Protection: Reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
- Risk Factor Management: Reduce cardiovascular events in adults with type 2 diabetes and multiple cardiovascular risk factors, even without established cardiovascular disease.
|
| Active Ingredient |
Semaglutide, a GLP-1 receptor agonist. |
Dulaglutide, a GLP-1 receptor agonist. |
| Benefits |
- Blood Sugar Control: Produces substantial reductions in blood glucose and HbA1c.
- Weight Management: May promote clinically meaningful weight loss.
- Cardiovascular Health: Reduces certain cardiovascular risks in eligible adults with type 2 diabetes.
- Kidney Health: Provides demonstrated benefits in specified patients with diabetic chronic kidney disease.
|
- Blood Sugar Control: Improves blood glucose and HbA1c in patients with type 2 diabetes.
- Cardiovascular Health: Reduces major cardiovascular events in eligible adults with diabetes and cardiovascular risk factors.
- Weight Management: May produce modest weight loss in some patients.
- Pediatric Diabetes: Provides an approved treatment option for children aged 10 and older with type 2 diabetes.
|
| Potential Health Risks |
- Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Eye Complications: Possible worsening of diabetic retinopathy.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
|
- Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Gastrointestinal Reactions: Potentially severe digestive symptoms.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
|
| Weight Loss Potential |
In the SUSTAIN 7 trial, Ozempic produced approximately 4.6–6.5 kg of average weight loss over 40 weeks at the studied doses. Results vary with dosage, patient characteristics, and treatment duration. Ozempic is not approved specifically for weight loss. |
In the SUSTAIN 7 trial, Trulicity produced approximately 2.3–3.0 kg of average weight loss over 40 weeks at the studied doses. Higher Trulicity doses were not evaluated in this comparison. Trulicity is not approved specifically for weight loss. |
| Administration |
- Injection: Subcutaneous injection once weekly.
- Injection Sites: Abdomen, thigh, or upper arm.
- Injection Devices: Available in prefilled injection presentations, depending on product supply.
|
- Injection: Subcutaneous injection once weekly.
- Injection Sites: Abdomen, thigh, or upper arm.
- Injection Device: Single-dose prefilled injection pen.
|
| Dosing Considerations |
- Starting Dose: Typically 0.25 mg weekly for four weeks.
- Dose Escalation: Gradual increases to 0.5 mg, 1 mg, or 2 mg weekly according to treatment response.
- Maximum Dose: 2 mg once weekly for glycemic control.
|
- Starting Dose: Typically 0.75 mg once weekly.
- Dose Escalation: Adults may increase to 1.5 mg, 3 mg, or 4.5 mg weekly based on response and tolerability.
- Maximum Dose: 4.5 mg weekly for adults; 1.5 mg weekly for pediatric patients.
|
| Who May Benefit Most? |
Adults with type 2 diabetes who need substantial A1C reduction, particularly those who may benefit from additional weight loss or meet its cardiovascular or kidney risk-reduction indications. |
Adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, and children aged 10 and older who need an approved GLP-1 treatment for type 2 diabetes. |
| How Fast Does It Work? |
- Blood Sugar: Improvements may begin within the first weeks.
- HbA1c: Reductions are generally assessed over approximately three months.
- Weight Loss: Typically develops gradually over several months.
|
- Blood Sugar: Improvements may begin within the first several weeks.
- HbA1c: Reductions are generally evaluated after approximately three months.
- Weight Changes: Modest weight loss may develop gradually over several months.
|
| Potential Side Effects |
- Digestive: Nausea, vomiting, diarrhea, abdominal pain, and constipation.
- Timing: Gastrointestinal symptoms frequently occur when starting treatment or increasing dosage.
|
- Digestive: Nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.
- Other Effects: Fatigue and indigestion may occur.
- Timing: Gastrointestinal symptoms frequently occur during treatment initiation and dose escalation.
|